SPYRE THERAPEUTICS, INC. Proceeds from Sale of Intangible Assets
SPYRE THERAPEUTICS, INC. (SYRE) reported Proceeds from Sale of Intangible Assets of $70.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. proceeds from sale of intangible assets for the quarter ending 2026-06-30 was $40.00M, a 471.43% increase year-over-year.
- SPYRE THERAPEUTICS, INC. proceeds from sale of intangible assets for the quarter ending 2026-03-31 was $30.00M.
- SPYRE THERAPEUTICS, INC. proceeds from sale of intangible assets for the quarter ending 2025-12-31 was $0.00.
- SPYRE THERAPEUTICS, INC. proceeds from sale of intangible assets for the quarter ending 2025-09-30 was $0.00.
- SPYRE THERAPEUTICS, INC. proceeds from sale of intangible assets for fiscal 2025 was $7.00M.
- SPYRE THERAPEUTICS, INC. proceeds from sale of intangible assets for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SPYRE THERAPEUTICS, INC. proceeds from sale of intangible assets for fiscal 2023 was $15.00M.
- SPYRE THERAPEUTICS, INC. proceeds from sale of intangible assets for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 6 month | Proceeds from Sale of Intangible Assets 9 month | Proceeds from Sale of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $70.00M 10-Q · filed 2026-08-04 | $70.00M derived: sum of 3 quarters · filed 2026-08-04 | $70.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $30.00M 10-Q · filed 2026-05-05 | $30.00M derived: sum of 2 quarters · filed 2026-05-05 | $30.00M derived: sum of 3 quarters · filed 2026-05-05 | $37.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $7.00M derived: sum of 3 quarters · filed 2026-08-04 | $7.00M 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $7.00M derived: sum of 2 quarters · filed 2026-08-04 | $7.00M 10-Q · filed 2025-11-04 | $7.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $7.00M 10-Q · filed 2026-08-04 | $7.00M derived: sum of 3 quarters · filed 2026-08-04 | $7.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $0.00 derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $15.00M 10-K · filed 2026-02-19 | ||
| 2023-09-30 | $15.00M 10-Q/A · filed 2024-11-18 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $0.00 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |